Cervical cancer is the third most common cancer
in women worldwide. Cervical cancer is a disease that develops quite slowly and
begins with a precancerous condition known as dysplasia. Dysplasia is easily
detected in a routine Pap smear and is completely treatable. Cervical cancer is
a malignant tumor deriving from cells of the cervix( lower part of the uterus).
The primary etiological agent is HPV and its
precursor lesions for cervical cancer, which leads the development of the
control of cervical cancer cells. With the help of HPV vaccine clinical trials
data, we easily to identify the characteristics and mechanisms of the immune
response. The complete perspective of immunotherapy treatment has not been
utilized. Clinical studies are the import factor in understanding the future of
immunotherapy (immune- Oncology) in treating cancer patients.
To stimulate immunity against cervical cancer in
treatment by using immunotherapy based drugs and vaccines involve Bevacizumab
(vascular endothelial growth factor-specific angiogenesis inhibitor) which has
received FDA approval for the treatment of cervical cancer, in combination with
paclitaxel and topotecan or paclitaxel and cisplatin in recurrent disease. Some
warnings are included like surgery and wound healing complications,
Gastrointestinal perforations, and hemorrhage with some common adverse
reactions are hypertension, back pain, headache, taste alteration, dry skin and
rectal hemorrhage. Gardasil is a vaccine has received FDA approval for the treatment
of cervical cancers caused by Human Papillomavirus (HPV) types 16 and 18. With
contraindications like hypersensitivity. Also, having Warning involves Syncope
sometimes associated with tonic-clonic movements with most common adverse
reaction involves headache, swelling, erythema, fever and nausea.
Some drugs and vaccines are under clinical trials
in cervical cancer. Ipilimumab (NCT01693783) is running in phase II under
safety and efficacy study design, which targets to kill cancer cells.
Ipilimumab with Cisplatin (NCT01711515) is running in phase I under safety
study design, which targets to the
growth of cancer cells. VGX-3100 and INO-9012 DNA vaccine (NCT02172911)
is running in phase I and II under safety and efficacy study, which targets to
HPV-16 or 18-positive. Peptide vaccine (NCT00108875) is running in phase I and
II under non randomized, safety and efficacy study, which targets to cancer
cells.
Global Allied Pharmaceuticals(GAP) has the
advance technology and the expert team of immunotherapy and immune-oncology.
Our team has capability for new development of the immunotherapeutic cancer
agents. Our expert team easily understand the molecular basis of the
interactions between targeted anti-cancer agents and the immune system and also
helps the patients in planning their treatment strategy throughout their
different types of solid tumor cancers like breast and prostate, melanoma,
cervical and colorectal.
For more information kindly visit us at www.gapsos.com
No comments:
Post a Comment